Globus Medical CFO Awarded 20,909 Stock Options; Vest Over 4 Years

Rhea-AI Filing Summary

Kyle Kline, Senior Vice President and Chief Financial Officer of Globus Medical (GMED), received an award of stock options on 07/18/2025. The grant totals 20,909 stock options to purchase Class A common stock at an exercise price of $56.34 per share. The options vest over four years with one-quarter vesting on the first anniversary of the vesting commencement date (07/18/2026) and the remainder vesting ratably each month over the following 36 months. The options expire on 07/18/2035 and are reported as directly beneficially owned following the transaction.

Positive

• Grant of 20,909 stock options provides a clear long‑term incentive for the CFO.
• Standard four‑year vesting schedule with one‑year cliff then monthly vesting supports retention.

Negative

• None.

Insights

Corporate Governance Expert

TL;DR: Routine, time‑based equity grant to a named officer, structured for retention and alignment with shareholders.

The Form 4 reports a standard option grant to the company's CFO totaling 20,909 options at a $56.34 exercise price, vesting over four years with a ten‑year term. This structure is common for senior executives and emphasizes retention through multi‑year vesting. The disclosure shows direct beneficial ownership of the granted options post‑award. There are no indications in the filing of accelerated vesting, transfers, or hedging arrangements, and no other transactions are reported that would materially change governance control.

Compensation Analyst

TL;DR: Typical long‑term incentive award sized for a senior officer, with clear vesting schedule and a ten‑year exercise window.

The award comprises 20,909 stock options exercisable at $56.34 and expiring on 07/18/2035, with one‑quarter vesting after one year and the remainder monthly over three years. This time‑based vesting aligns executive incentives with multi‑year performance and retention goals. The filing does not disclose grant valuation, target performance metrics, or whether the award is part of a broader annual award program, limiting deeper compensation benchmarking.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Kline Kyle

(Last) (First) (Middle)

VALLEY FORGE BUSINESS CENTER

2560 GENERAL ARMISTEAD AVENUE

(Street)

AUDUBON PA 19403

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
GLOBUS MEDICAL INC [ GMED ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Senior Vice President, CFO

3. Date of Earliest Transaction (Month/Day/Year)
07/18/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy Class A Common Stock)	$56.34	07/18/2025		A		20,909		(1)	07/18/2035	Class A Common Stock	20,909	$0	20,909	D

Explanation of Responses:

1. These options were granted on July 18, 2025, and vest over a four-year period with one-fourth (1/4) of the options granted vesting on July 18, 2026, the first anniversary of the vesting commencement date, and the balance of the options granted vesting ratably on a monthly basis over the following 36 months.

	/s/ Kelly G. Huller, Attorney-in-Fact	08/27/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What did Kyle Kline (GMED) receive on 07/18/2025?

Kyle Kline received 20,909 stock options to purchase Class A common stock at an exercise price of $56.34 per share.

When do the options granted to Kyle Kline vest and expire?

One‑quarter vests on 07/18/2026, then the balance vests monthly over the next 36 months; the options expire on 07/18/2035.

How many options does Kyle Kline beneficially own after the transaction?

20,909 options are reported as directly beneficially owned following the transaction.

What is the exercise price for the options awarded to the CFO?

The exercise price is $56.34 per share for the awarded stock options.

Does the Form 4 indicate any transfers or sales of securities by Kyle Kline?

No. The filing reports only an option grant (acquisition) and shows the resulting beneficial ownership; no dispositions or transfers are listed.